VRDN
Viridian Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.78B
P/E Ratio
—
EPS
$-3.35
Beta
0.90
52W High
$34.29
52W Low
$13.18
50-Day MA
$15.85
200-Day MA
$24.22
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
1.01
PEG Ratio
—
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
Fundamentals
| Revenue (TTM) | $70.92M |
| Gross Profit (TTM) | $-268.72M |
| EBITDA | $-385.23M |
| Operating Margin | -82389.00% |
| Return on Equity | -58.10% |
| Return on Assets | -33.30% |
| Revenue/Share (TTM) | $0.79 |
| Book Value | $4.92 |
| Price-to-Book | 3.53 |
| Price-to-Sales (TTM) | 25.13 |
| EV/Revenue | 16.94 |
| EV/EBITDA | -3.18 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 95.80% |
| Shares Outstanding | $110.43M |
| Float | $103.02M |
| % Insiders | 0.14% |
| % Institutions | 109.18% |
Historical Volatility
HV 10-Day
57.78%
HV 20-Day
59.42%
HV 30-Day
101.64%
HV 60-Day
127.28%
HV Rank
85.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($33.94 target)
3
Strong Buy13
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026